Part 1 Basic Information

Name: Weiping Zheng

Address: School of Pharmacy, Jiangsu University, 301 Xuefu Road, Zhenjiang, Jiangsu 212013, China

Email: wzheng@ujs.edu.cn

Part 2 Personal Profile

Dr. Weiping Zheng is a full professor and M.S./Ph.D. supervisor at School of Pharmacy, Jiangsu University, and a Jiangsu provincial specially-appointed professor and a recipient of the Jiangsu provincial ‘‘innovation and venture talents’’ award. His research is focused on medicinal chemistry and chemical biology. He has been the principal investigator of four(4) national and provincial research grants and has published 45 scholastic papers in peer-reviewed top international scientific journals, including those on Cancer Cell and Chemical Society Reviews. He was invited to edit a monograph for Elsevier and write two books for Royal Society of Chemistry. He was included in the “2026 Top 2% Scientists list with career‑long impact” (total 93 scholars included at Jiangsu University), which was jointly produced and disclosed in October, 2026 by Stanford University and Elsevier. He has served as a reviewer for over twenty(20) international scientific journals including Journal of the American Chemical Society, Journal of Medicinal Chemistry, and Cell Chemical Biology.

Part 3 Education

•1994.08—1999.07, University of Tennessee, USA, Medicinal Chemistry, Ph.D.

•1987.09—1990.09, Shanghai Institute of Materia Medica, Chinese academy of Sciences, Organic Chemistry, M.S.

•1983.09—1987.07, Zhejiang Normal University, Chemistry, B.S.

Part 4 Work Experience

•2012.01–Present, School of Pharmacy, Jiangsu University, Professor and M.S./Ph.D. Supervisor

•2004.08—2011.08, Department of Chemistry, University of Akron, Endowed Assistant Professor (tenure-track) and M.S./Ph.D. Supervisor

•2002.07—2004.08, Johns Hopkins University School of Medicine, Research Associate (non-tenure-track)

•1999.07—2002.06, Johns Hopkins University School of Medicine, Post-doctoral Fellow.

Part 5 Research Interests

1.Medicinal Chemistry: to develop inhibitors and activators for the epigenetic enzymatic reactions

2.Chemical Biology: to develop and apply the chemical biology probes for enzymatic reactions.

3.Cancer Medicinal Chemistry and Pharmacology.

Part 6 Research Achievements

6.1 Research Projects

•2016.01—2019.12 | National Natural Science Foundation of China General Grant “Developing potential anti-cancer therapeutics based on disrupting the p110alpha[E545K]-IRS1 interaction” (Grant No. 21572080) | NSFC | Principal Investigator

•2013.01—2016.12｜National Natural Science Foundation of China General Grant “Mechanism-based SIRT1/SIRT2 dual inhibitors containing N(epsilon)-thioacetyl-lysine” (Grant No. 21272094) | NSFC | Principal Investigator

•2013—2015｜Jiangsu provincial “innovation and venture talents” grant｜Principal Investigator

•2012—2015｜“Jiangsu provincial specially-appointed professorship” grant｜Principal Investigator

6.2 Publications (representative)

1.Zheng, Weiping*. The (patho)physiological roles of the individual deacylase activities of a sirtuin[J]. Chemical Biology & Drug Design, 2024, 103: e14460. (SCI Q3, IF=3.3)

2.Li, Renwu; Yan, Lingling; Sun, Xun*; Zheng, Weiping*. A bicyclic pentapeptide-based highly potent and selective pan-SIRT1/2/3 inhibitor harboring N(epsilon)-thioacetyl-lysine[J]. Bioorganic & Medicinal Chemistry, 2020, 28: 115356. (SCI Q2, IF=3.5)

3.Jiang, Yanhong; Liu, Jiajia; Chen, Di; Yan, Lingling; Zheng, Weiping*. Sirtuin inhibition: strategies, inhibitors, and therapeutic potential[J]. Trends in Pharmacological Sciences, 2017, 38: 459-472. (SCI Q1, IF=19.9)

4.Liu, Jiajia; Zheng, Weiping*. Cyclic peptide-based potent human SIRT6 inhibitors[J]. Organic & Biomolecular Chemistry, 2016, 14: 5928-5935. (SCI Q2, IF=2.8)

5.Chen, Bing; Zang, Wenwen; Wang, Juan; Huang, Yajun; He, Yanhua; Yan, Lingling; Liu, Jiajia; Zheng, Weiping*. The chemical biology of sirtuins[J]. Chemical Society Reviews, 2015, 44: 5246-5264. (SCI Q1, IF=48.3)

6.Hao, Yujun; Wang, Chao; Cao, Bo; Hirsch, Brett M.; Song, Jing; Markowitz, Sanford D.; Ewing, Rob M.; Sedwick, David; Liu, Lili; Zheng, Weiping*; Wang, Zhenghe*. Gain of interaction with IRS1 by p110α helical domain mutants is crucial for their oncogenic functions[J]. Cancer Cell, 2013, 23: 583-593. (SCI Q1, IF=56.1)

6.3 Monographs and Textbooks

•Weiping Zheng (editor). “Sirtuins in Health and Disease”. Amsterdam: Elsevier, 2018. ISBN-10: 0128122617, ISBN-13: 978-0128122617.

•Weiping Zheng (sole author). “Active Site-directed Enzyme Inhibitors: Design Concepts”. London: Royal Society of Chemistry, 2023. ISBN-10: 1839161973, ISBN-13: 978-1839161971.

•Weiping Zheng (sole author). “Non-active Site-directed Enzyme Inhibitors: Design Concepts”. London: Royal Society of Chemistry, in press. ISBN-10: 1837674116, ISBN-13: 978-1837674114.